Article
Pharmacology & Pharmacy
Seung-Ah Lee, Weon Kim, Taek Jong Hong, Youngkeun Ahn, Moo Hyun Kim, Soon Jun Hong, Bong Sik Kim, Seok Yeon Kim, In-Ho Chae, Byung Jin Kim, Moo-Yong Rhee, Joon Han Shin, Tae Soo Kang, Jin Man Cho, Jung-Sun Kim, Cheol Whan Lee
Summary: The combination therapy of low-intensity rosuvastatin and ezetimibe was found to be more effective in reducing LDL cholesterol levels in patients requiring cholesterol lowering therapy compared to monotherapy, with rare adverse effects observed across all treatment groups.
CLINICAL THERAPEUTICS
(2021)
Article
Cardiac & Cardiovascular Systems
Leonardo De Luca, Pier Luigi Temporelli, Michele Massimo Gulizia, Lucio Gonzini, Tiziana Anita Ammaturo, Luigi Tedesco, Silvia Pede, Fabrizio Oliva, Domenico Gabrielli, Furio Colivicchi, Maurizio R. Averna
Summary: This study evaluated the predictive role of hypertriglyceridemia in patients with chronic coronary syndromes treated with statins, but found that elevated triglyceride levels were not an independent predictor of major adverse cardio-cerebrovascular events at 1 year.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2023)
Article
Clinical Neurology
Pierre Amarenco, Jong S. Kim, Julien Labreuche, Hugo Charles, Maurice Giroud, Byung-Chul Lee, Philippa C. Lavallee, Marie-Helene Mahagne, Elena Meseguer, Norbert Nighoghossian, Philippe Gabriel Steg, Eric Vicaut, Eric Bruckert
Summary: In patients with atherosclerotic stroke, targeting an LDL cholesterol level <70 compared to 100+/-10 mg/dL with a combination of statin and ezetimibe consistently reduced the risk of subsequent stroke.
Article
Pharmacology & Pharmacy
Ming-Ting Chou, Anthony McGirr, Gwo-Ping Jong, Ting-Hsing Chao, I-Te Lee, Chun-Yao Huang, Ching-Pei Chen, Chang-Hsun Hsieh, Chieh-Hsiang Lu, Wayne Huey-Herng Sheu
Summary: This study demonstrates that 1PC111 is more effective than either ezetimibe or pitavastatin alone in treating hypercholesterolemia. The use of 1PC111 may benefit elderly patients in particular.
CLINICAL THERAPEUTICS
(2022)
Article
Multidisciplinary Sciences
Jihaeng Im, Erisa Kawada-Watanabe, Junichi Yamaguchi, Hiroyuki Arashi, Hisao Otsuki, Yuko Matsui, Haruki Sekiguchi, Shinya Fujii, Fumiaki Mori, Hiroshi Ogawa, Nobuhisa Hagiwara
Summary: The study evaluated the impact of baseline low-density lipoprotein cholesterol on the outcomes of acute coronary syndrome patients receiving different statin therapies. The results indicated that patients with low LDL-C levels did not benefit from combination therapy, while those with high LDL-C levels showed better clinical results with combination therapy compared to monotherapy.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Juying Qian, Zhanquan Li, Xuelian Zhang, Jiyan Chen, Chunhua Ding, Ping Yang, Yan Liu, Miao Shi, Xinru Ren, Junbo Ge
Summary: This study compared the efficacy and tolerability of a fixed-dose combination of ezetimibe/atorvastatin (EZ/AS) with those of escalating doses of atorvastatin monotherapy in Chinese patients with hypercholesterolemia uncontrolled with statin monotherapy. The results showed that the combination therapy was more effective in improving LDL-C levels compared to the monotherapy, and had a similar tolerability profile.
CLINICAL THERAPEUTICS
(2022)
Review
Biochemistry & Molecular Biology
Assunta Di Costanzo, Ciro Indolfi, Sabato Sorrentino, Giovanni Esposito, Carmen Anna Maria Spaccarotella
Summary: This review examines the interaction between dyslipidemia, platelet function, and drug treatments. It provides an overview of the effects of hypolipidemic drugs on platelet function and discusses the role of statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl as antithrombotics. The review also highlights the importance of cholesterol-lowering therapy in reducing cardiovascular events.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cardiac & Cardiovascular Systems
Luke J. Laffin, Dennis Bruemmer, Michelle Garcia, Danielle M. Brennan, Ellen McErlean, Douglas S. Jacoby, Erin D. Michos, Paul M. Ridker, Tracy Y. Wang, Karol E. Watson, Howard G. Hutchinson, Steven E. Nissen
Summary: This study compared the efficacy of a low-dose statin with placebo and 6 common supplements in impacting lipid and inflammatory biomarkers. The results showed that rosuvastatin significantly lowered LDL-C compared to placebo and each supplement. None of the dietary supplements demonstrated a significant decrease in LDL-C compared to placebo.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Genetics & Heredity
Ilhame Diboun, Yasser Al-Sarraj, Salman M. Toor, Shaban Mohammed, Nadeem Qureshi, Moza S. H. Al Hail, Amin Jayyousi, Jassim Al Suwaidi, Omar M. E. Albagha
Summary: This study investigated the genetic spectrum and estimated the prevalence of familial hypercholesterolemia (FH) in Qatar by combining whole-genome sequencing data and deep phenotype data. The results revealed an estimated prevalence of 0.8% for definite/probable cases of FH in the Qatari population and identified known pathogenic and possibly pathogenic mutations associated with FH.
FRONTIERS IN GENETICS
(2022)
Article
Medicine, General & Internal
Federica Fogacci, Marina Giovannini, Elisa Grandi, Egidio Imbalzano, Daniela Degli Esposti, Claudio Borghi, Arrigo F. G. Cicero
Summary: The objective of this study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after the recent enlargement of reimbursement criteria. Based on our observations, the application of enlarged reimbursement criteria for PCSK9 inhibitors could mildly improve the management of high-risk hypercholesterolemic subjects in the outpatient lipid clinic.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Heather Burnett, Kyle Fahrbach, Allie Cichewicz, Ramandeep Jindal, Jialu Tarpey, Adeline Durand, Maximiliano Di Domenico, Andreas Reichelt, Adie Viljoen
Summary: This study used network meta-analysis to compare the relative efficacy of inclisiran, alirocumab, evolocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia. The results showed that inclisiran, alirocumab, and evolocumab are expected to provide similar clinically meaningful improvements in low-density lipoprotein cholesterol.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Health Care Sciences & Services
Victoria Korneva, Tatyana Kuznetsova, Ulrich Julius
Summary: Cumulative LDL-C level plays an important role in the development of coronary heart disease (CHD) in patients with familial hypercholesterolemia (FH), and the index cumulative LDL-C/age also has a predictive role.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Jiayu Li, Yanguo Xin, Jingye Li, Meng Meng, Li Zhou, Hui Qiu, Hui Chen, Hongwei Li
Summary: In Chinese patients with acute coronary syndrome, the Sampson equation is more accurate for evaluating LDL-C levels compared to the Friedewald equation, especially in patients with high triglyceride levels. The Sampson equation also demonstrates greater accuracy in subgroups of different baseline characteristics and comorbidities.
LIPIDS IN HEALTH AND DISEASE
(2022)
Article
Medicine, General & Internal
Byeong-Keuk Kim, Sung-Jin Hong, Yong-Joon Lee, Soon Jun Hong, Kyeong Ho Yun, Bum-Kee Hong, Jung Ho Heo, Seung-Woon Rha, Yun-Hyeong Cho, Seung-Jun Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Summary: Through a randomized trial, it was found that the combination therapy of moderate-intensity statin and ezetimibe is as effective as high-intensity statin monotherapy in reducing cardiovascular events and maintaining stable LDL cholesterol concentrations, with better drug tolerance.
Article
Cardiac & Cardiovascular Systems
Hayato Tada, Kan Yamagami, Nobuko Kojima, Junichi Shibayama, Tetsuo Nishikawa, Hirofumi Okada, Akihiro Nomura, Soichiro Usui, Kenji Sakata, Masayuki Takamura, Masa-aki Kawashiri
Summary: The study revealed that the prevalence of APOE7 mutant among patients clinically diagnosed with FH was higher than expected, especially among those without other causative mutations. This suggests that APOE7 mutant may be one of the causes of FH, particularly in individuals without FH mutations.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)